Researchers provide essential insights on the molecular activation of the MAP kinase p38?, the final switch triggering the inflammatory response. Inflammation is a cellular coping mechanism when ...

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...

In the wee hours of an October morning, David Baker, a protein biologist at the University of Washington (UW), received the most-awaited phone call in a scientist’s career. Halfway around the world, ...

A publication from Acta Pharmaceutica Sinica B discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting serine/threonine-protein ...

Protein kinases, including p38α, have therefore been heavily studied. The first protein kinase structure was solved 30 years ago – a landmark in the field – and many more structures have followed, ...

Protein kinase inhibitors represent a major advance in cancer treatment due to their ability to target the specific kinases involved in tumor growth and survival. More than 80 small-molecule protein ...